Navigation Links
New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery

Results Presented at the American Academy of Otolaryngology-Head and Neck

Surgery Annual Meeting

CHICAGO, Sept. 24 /PRNewswire/ -- In studies presented this week at the American Academy of Otolaryngology-Head and Neck Surgery Annual Meeting, researchers found that Coblation(R)-assisted procedures eliminated the risk of airway fires, and Coblation(R)-Assisted Sinus Surgery (CASS) procedures lowered the risk of blood loss in nasal polypectomy/endoscopic sinus surgery (ESS).

Results of a study, sponsored by ArthroCare and entitled, "Device-Related Risk of Airway Fire in Oropharyngeal Surgery," presented today on the podium by Soham Roy, MD, a member of ArthroCare's Strategic Advisory Board for its ENT division, and Lee Smith, MD, compared the risk of airway fire for an electrosurgical device (Bovie) and a bipolar radiofrequency ablation wand (Coblator(R)) in a mechanical chicken cavity model. Their study found that the risk of airway fire appeared to be eliminated with Coblation, while electrosurgical devices, such as Bovie, present a significant risk of fire during open cavity surgery in oxygen-enriched environments. All experimental conditions were tested for four minutes, or until a positive result was achieved and were repeated in another model to ensure accuracy.

"Intraoperative fires are a well-described and devastating complication of oropharyngeal and airway surgery, some leading to severe injury and/or death," said Dr. Roy, lead investigator of the study from Children's ENT of Houston and Texas ENT Consultants. "We are currently conducting further investigations to determine the risk of airway fire with other surgical modalities, including laser, which is commonly used in ENT procedures."

At the American Rhinologic Society Fall Meeting, conducted in tandem with AAO-HNS, a study, entitled "Effect of Coblation Polypectomy on Estimated Blood Loss in Endoscopic Sinus Surgery (ESS): A Pilot Study," found that CASS was associated with a statistically significant lower estimated blood loss and blood loss per minute when compared to traditional microdebridement technique.

Surgical management of refractory chronic rhinosinusitis with nasal polyposis is typically successfully performed using ESS.(1.,2.) "Despite numerous advances in surgical instrumentation and optical aids, intraoperative hemorrhage remains a major hurtle in ESS with sinonasal polyposis," said Jose W. Ruiz, III, MD, investigator of the study and assistant professor at the University of Miami, Department of Otolaryngology. "Since adopting Coblation, reduced blood loss and improved surgical visualization have reduced our concern for complications, including orbital and intracranial injuries." The study concluded that Coblation represents a viable alternative to microdebridement for patients with nasal polyps undergoing ESS as it resulted in better visualization as a result of better homeostasis. The study was a retrospective analysis of 25 patients with nasal polyposis undergoing ESS and was conducted by investigators Jean Anderson Eloy, MD, Thomas J. Walker, MD, Roy R. Casiano, MD and Jose W. Ruiz, III, MD.

The Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) runs from September 21-24, 2008 at the McCormick Place Convention Center in Chicago, IL.


1. Bhattacharyya N. Progress in surgical management of chronic

rhinosinusitis and nasal polyposis. Curr Allergy Asthma Rep

7(3):216-220, 2007.

2. Bhattacharyya N. Influence of polyps on outcomes after endoscopic sinus

surgery. Laryngoscope 117(10):1834-1838, 2007.


Founded in 1993, ArthroCare Corporation ( is a highly innovative, multi-business medical device company that develops, manufactures and markets minimally invasive surgical products. With these products, ArthroCare targets a multi-billion dollar market opportunity across several medical specialties, significantly improving existing surgical procedures and enabling new, minimally invasive procedures. Many of ArthroCare's products are based on its patented Coblation(R) technology, which uses low-temperature radiofrequency energy to gently and precisely dissolve rather than burn soft tissue -- minimizing damage to healthy tissue. Used in more than four million surgeries worldwide, Coblation(R)-based devices have been developed and marketed for sports medicine; spine/neurologic; ear, nose and throat (ENT); cosmetic; urologic and gynecologic procedures. ArthroCare also has added a number of novel technologies to its portfolio, including Opus Medical sports medicine, Parallax spine and Applied Therapeutics ENT products, to complement Coblation(R) within key indications.


The information provided in this press release includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding the strength or expected benefits of the Company's technology. Statements that are not historical facts are forward-looking statements. These statements are based on beliefs and assumptions by management, and on information currently available to management. Forward-looking statements speak only as of the date they are made, and ArthroCare undertakes no obligation to update any of them publicly in light of new information or future events. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Examples of these factors include, but are not limited to, the strength of the Company's technology and its continued adoption, unanticipated accounting issues or audit issues regarding the financial data for the periods being restated in the Company's previously announced restatement; the ability of the Company and its independent registered public accounting firm to confirm information or data identified in the review, being overseen by the Audit Committee of the Company's Board of Directors, of the scope and nature of the Company's internal controls (the "Review"); unanticipated issues regarding the Review that prevent or delay the Company's independent registered public auditing firm from relying upon the Review or that require additional efforts, documentation, procedures, review or investigation; the Company's ability to design or improve internal controls to address issues detected in the Review or by management in its reassessment of the Company's internal controls; the impact upon the Company's operations of the Review, legal compliance matters or internal controls, improvement and remediation; difficulties in controlling expenses, including costs of the Review, legal compliance matters or internal controls review, improvement and remediation; the Company's ability to become current in its SEC periodic reporting requirements; the outcome of pending litigation; general business, economic and political conditions; competitive developments in the medical devices market; changes in applicable legislative or regulatory requirements; the Company's ability to effectively and successfully implement its financial and strategic alternatives, as well as business strategies, and manage the risks in its business; the reactions of the marketplace to the foregoing; and other risks and uncertainties discussed more fully in the Company's SEC filings, including those discussed under Item 1A. "Risk Factors" in its Form 10-K for the fiscal year ended December 31, 2007.

SOURCE ArthroCare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare ... 7% over 2015-2016. Latin America has ... , (excluding Japan ), is second ... continues to face increased healthcare expenditure. In 2013-2014, total ... declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. In ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, ... choose to buy during the Black Friday and Cyber Monday massage chair sales ... search the Internet high and low to find the best massage chair deals, they ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... PRMA Plastic ... November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , ... wake up every day excited to rebuild lives and it’s an honor to have ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):